Select Session

Welcome Introduction: The Evolving and Complex Therapeutic Landscape for Multiple Sclerosis: Achieving the Ideal Balance Between Safety and Efficacy for Long-Term Treatment In the Managed Care Setting
Douglas R. Jeffery, MD, PhD – Program Chairman

Trial-Based Evidence for First Line Therapy with Immune- Modulating Agents: From Mechanisms to Therapy—Landmark Studies, Long-Term Safety Data, and Clinical Experience with IMTs in the Managed Care Environment
Douglas R. Jeffery, MD, PhD – Program Chairman

The Emergence of Oral Immunosuppressive and Other Agents for MS: What Do We Know (or Not Know) About Their Safety and Efficacy?
Howard Zwibel, MD

The Changing MS Therapeutic Landscape: Perspectives of an MS-Focused Pharmacist—How Will We Need to Adapt to and Analyze the New Generation of MS Therapies?g in Patients Requiring SPAF: Aligning Appropriate Therapies in Low, Moderate, and High Risk Groups with AF—Strategies and Suggestions
Ronald DeBellis, PharmD

The Role of Comparative Effectiveness Guidelines, Long Term Safety Considerations, and Monitoring Costs for Evaluating Therapies for MS
Monica Mehta, PharmD